UnitedHealth Beats Forecasts as Medicare Probe Clouds Recovery Path
- UnitedHealth posted stronger-than-expected quarterly earnings and raised its full-year guidance, signaling renewed momentum in its core insurance operations.
- The upbeat results follow a turbulent stretch earlier this year, when the company’s stock plunged amid leadership changes and a federal probe into its Medicare billing practices.
Key Takeaways
UnitedHealth Group (UNH) posted third-quarter adjusted earnings of $2.92 per share, topping analyst estimates of $2.74. Revenue rose 12% year-over-year to $113.16 billion, aligning with expectations. The company also raised its full-year EPS outlook to at least $16.25, up from $16.
The results come after a turbulent year marked by leadership changes and a federal investigation into Medicare billing practices. Shares surged early Tuesday but remain down 28% for the year, reflecting investor caution despite signs of operational improvement.
UnitedHealth Stock Rebounds After Strong Q3 Earnings and Raised Forecast
UnitedHealth Group is showing early signs of a rebound after a rocky year. The insurer reported third-quarter adjusted earnings of $2.92 per share, beating analyst expectations of $2.74. Revenue climbed 12% year-over-year to $113.16 billion, meeting forecasts.
The company also lifted its full-year adjusted EPS outlook to at least $16.25, up from its previous projection of $16. Shares surged Tuesday on the news but later trimmed gains. Despite the earnings beat, UnitedHealth stock remains down 28% in 2025, reflecting lingering investor caution amid regulatory scrutiny.
UnitedHealth Group’s stronger-than-expected earnings may indicate early signs of recovery after a volatile stretch marked by executive turnover and intensified scrutiny over its Medicare billing practices. The raised outlook suggests the insurer is regaining operational footing despite lingering regulatory pressure.
UnitedHealth’s upgraded outlook follows a turbulent period marked by executive upheaval and regulatory pressure. The company suspended its forecast earlier this year after then-CEO Andrew Witty abruptly stepped down in May, triggering a sharp stock decline.
In July, reports surfaced that former employees and medical professionals were interviewed by the Department of Justice regarding a probe into UnitedHealth’s Medicare billing practices, intensifying investor concerns.
New CEO Stephen Hemsley said Tuesday the company is “focused on strengthening performance and positioning for durable and accelerating growth in 2026 and beyond,” adding that the latest results reflect solid execution toward that goal.
